Hartman Institute for Therapeutic Organ Regeneration

Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR.

TitleKaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR.
Publication TypeJournal Article
Year of Publication2003
AuthorsBais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, Silverstein RL, Rafii S, Mesri EA
JournalCancer Cell
Volume3
Issue2
Pagination131-43
Date Published2003 Feb
ISSN1535-6108
KeywordsApoptosis, Cell Transformation, Neoplastic, Cells, Cultured, Endothelial Growth Factors, Endothelium, Vascular, Herpesvirus 8, Human, Humans, Intercellular Signaling Peptides and Proteins, Lymphokines, Phosphatidylinositol 3-Kinases, Phosphorylation, Protein Serine-Threonine Kinases, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-akt, Receptors, Chemokine, Retroviridae, Sarcoma, Kaposi, Signal Transduction, Telomerase, Telomere, Umbilical Veins, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factors, Viral Proteins
Abstract

The G protein-coupled receptor oncogene (vGPCR) of the Kaposi's sarcoma (KS) associated herpesvirus (KSHV), an oncovirus implicated in angioproliferative neoplasms, induces angiogenesis by VEGF secretion. Accordingly, we found that expression of vGPCR in human umbilical vein endothelial cells (HUVEC) leads to immortalization with constitutive VEGF receptor-2/ KDR expression and activation. vGPCR immortalization was associated with anti-senescence mediated by alternative lengthening of telomeres and an anti-apoptotic response mediated by vGPCR constitutive signaling and KDR autocrine signaling leading to activation of the PI3K/AKT pathway. In the presence of the KS growth factor VEGF, this mechanism can sustain suppression of signaling by the immortalizing gene. We conclude that vGPCR can cause an oncogenic immortalizing event and recapitulate aspects of the KS angiogenic phenotype in human endothelial cells, pointing to this gene as a pathogenic determinant of KSHV.

DOI10.1016/s1535-6108(03)00024-2
Alternate JournalCancer Cell
PubMed ID12620408
Grant ListAI 391920 / AI / NIAID NIH HHS / United States
R01 CA 91574 / CA / NCI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065